|
|
 |
Our Product Pipeline: Solid, and Set for Further Growth
Identifying and developing products that will improve the health and quality of life of patients remains a primary focus of Forest Laboratories. Our current product pipeline includes therapies in all stages of development and across a wide range of therapeutic areas, including asthma, cardiovascular disease, fibromyalgia, Alzheimer’s disease, chronic obstructive pulmonary disease, and infectious disease. The following is a partial listing of our pipeline products, in alphabetical order:
| Aclidinium for chronic obstructive pulmonary disease |
| Aclidinium + Formoterol for chronic obstructive pulmonary disease |
| Ceftaroline acetate for complicated skin and skin structure infections and community acquired pneumonia for hospitalized patients |
| Ceftaroline + NXL104 for hospital infections |
| Lexapro for adolescent depression |
| Linaclotide for chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C) |
| ME1036 for bacterial infections |
| Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease |
| Milnacipran for fibromyalgia |
| Nebivolol for congestive heart failure |
| Neramexane for Alzheimer’s disease |
| Oglemilast for chronic obstructive pulmonary disease and asthma |
| RGH-188 for schizophrenia and bipolar mania |
| RGH-896 for pain |
Except for the historical information contained herein, this page contains forward-looking statements within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.
|
|